Literature DB >> 20232511

[Prevalence of psychosis/substance abuse comorbidity. Clinical-epidemiological findings from different treatment settings in a large German city].

T Schnell1, K Neisius, J Daumann, E Gouzoulis-Mayfrank.   

Abstract

Comorbid substance use disorders in schizophrenia are of high clinical relevance, because they are common and they are mostly associated with an unfavourable long-term prognosis. Whereas the clinical impression suggests a continuous increase of substance use disorders in patients with schizophrenia over the last 10-20 years, results from epidemiological studies have been inconsistent. The aim of the present investigation was to study the prevalence of substance use disorders within a large sample of patients with schizophrenia in a large German city (Cologne). The prevalence data were examined in different treatment settings (outpatient vs inpatient, university hospital vs mental health hospital). Risk factors for substance use disorders and preferences for specific substances were analysed. The lifetime prevalence of comorbid substance use disorders in the entire sample of 2,337 patients with schizophrenia was 29.4%. However, the data varied substantially depending on the setting of treatment, with the highest comorbidity rates being prevalent in the inpatient sample. Alcohol and cannabis were the most commonly used substances. Commonly recognized risk factors for substance use disorders, such as being male and unmarried and having a low education level, were replicated.

Entities:  

Mesh:

Year:  2010        PMID: 20232511     DOI: 10.1007/s00115-009-2862-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  20 in total

1.  Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London.

Authors:  P J Duke; C Pantelis; M A McPhillips; T R Barnes
Journal:  Br J Psychiatry       Date:  2001-12       Impact factor: 9.319

Review 2.  Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.

Authors:  E Cantor-Graae; L G Nordström; T F McNeil
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

3.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

4.  Substance abuse and the onset of schizophrenia.

Authors:  M Hambrecht; H Häfner
Journal:  Biol Psychiatry       Date:  1996-12-01       Impact factor: 13.382

Review 5.  Cannabis and psychosis.

Authors:  David M Fergusson; Richie Poulton; Paul F Smith; Joseph M Boden
Journal:  BMJ       Date:  2006-01-21

6.  Patterns of current and lifetime substance use in schizophrenia.

Authors:  I L Fowler; V J Carr; N T Carter; T J Lewin
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

7.  Prevalence of substance misuse in first-episode psychosis.

Authors:  R Cantwell; J Brewin; C Glazebrook; T Dalkin; R Fox; I Medley; G Harrison
Journal:  Br J Psychiatry       Date:  1999-02       Impact factor: 9.319

Review 8.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

9.  The role of cannabis in cognitive functioning of patients with schizophrenia.

Authors:  Thomas Schnell; Dagmar Koethe; Jörg Daumann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2009-03-27       Impact factor: 4.530

10.  Correlates of patterns of substance abuse among patients with schizophrenia.

Authors:  B J Cuffel; K A Heithoff; W Lawson
Journal:  Hosp Community Psychiatry       Date:  1993-03
View more
  4 in total

1.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

2.  [Substance use associated disorders: frequency in patients with schizophrenic and affective psychoses].

Authors:  L Hermle; R Szlak-Rubin; K L Täschner; P Peukert; A Batra
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

3.  Cannabis use and cognitive dysfunction.

Authors:  Amresh Shrivastava; Megan Johnston; Ming Tsuang
Journal:  Indian J Psychiatry       Date:  2011-07       Impact factor: 1.759

4.  Effect of criminal justice mandate on drug treatment completion in women.

Authors:  Nyaradzo Longinaker; Mishka Terplan
Journal:  Am J Drug Alcohol Abuse       Date:  2014-02-14       Impact factor: 3.829

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.